NIS基因在恶性肿瘤中的研究进展  

Progress in Sodium Iodide Symporter for Tumors

作　　者：柴文文[1] 胡硕[1] 

机构地区：[1]中南大学湘雅医院,湖南长沙410008

出　　处：《肿瘤学杂志》2013年第12期914-918,共5页Journal of Chinese Oncology

摘　　要：恶性肿瘤的发生严重威胁着人类的生命健康。将基因治疗与靶向核素治疗相结合,即"基因靶向核素治疗"为肿瘤基因治疗开辟了一条崭新的途径。钠碘转运体(NIS)是存在于甲状腺滤泡细胞基底膜上的一种跨膜糖蛋白,介导碘的主动摄取,其摄碘功能是临床上治疗甲状腺疾病的基础。随着NIS基因的成功克隆以及基因治疗手段的发展,通过将NIS基因转染到甲状腺及非甲状腺肿瘤中,为131I靶向治疗恶性肿瘤的研究提供了新的思路。Cancer is still a serious disease.The combination of gene therapy and targeted radiotherapy will be a novel approach to tumor gene therapy,that means ＂Genetic Radiotherapy Targeting Therapy＂.The sodium iodide symporter（NIS）,located in thyroid follicular basement membrane,is a transmembrane glycoprotein responsible for uptake of iodide into cells.The ability of uptake iodide is also an important mechanism to treat the thyroid disease.At the same time,the cloning and characterization of NIS and the development of gene therapy methods make it possible to treat nonthyroid tumors that cannot accumulate iodide using radioiodine mediated by NIS.That will provide a new idea targeting to cancer with 131I.

关 键 词：钠碘转运体 基因治疗 肿瘤 放射性核素 

分 类 号：R73[医药卫生—肿瘤]